FDC shines on launching oral suspension of Favipiravir

13 Jul 2021 Evaluate

FDC is currently trading at Rs. 383.00, up by 8.40 points or 2.24% from its previous closing of Rs. 374.60 on the BSE.

The scrip opened at Rs. 389.00 and has touched a high and low of Rs. 389.00 and Rs. 380.20 respectively. So far 19229 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 404.90 on 15-Jun-2021 and a 52 week low of Rs. 236.60 on 14-Jul-2020.

Last one week high and low of the scrip stood at Rs. 389.00 and Rs. 353.30 respectively. The current market cap of the company is Rs. 6323.63 crore.

The promoters holding in the company stood at 69.35%, while Institutions and Non-Institutions held 9.73% and 20.92% respectively.

FDC has launched oral suspension of Favipiravir to treat mild to moderate cases of COVID-19 in the country. This prescription-only Favenza oral suspension is currently available at all retail medical outlets and hospital pharmacies across India. Convenient loading dosage of the oral suspension helps reduce dosage frequency.

FDC is engaged in manufacture of specialized formulations, and oral rehydration salts (ORS).


FDC Share Price

422.20 14.75 (3.62%)
29-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1717.50
Dr. Reddys Lab 1268.60
Cipla 1494.40
Zydus Lifesciences 904.00
Lupin 2079.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×